Dual Approach of Next-Gen Vectorized Gene Therapy and Vectorized Antibodies
Revolutionizing Treatment for Neurodegenerative Diseases and Beyond
The promise of vectorized gene therapy has ignited a beacon of hope for individuals battling debilitating central nervous system (CNS) proteinopathies and rare neurological diseases. Our groundbreaking pipeline, spearheaded by state-of-the-art vectorized gene therapy, is poised to halt disease progression and restore function in patients grappling with some of the most challenging diseases and conditions to treat.
At the forefront of our efforts lies Parkinson's disease, a neurodegenerative disorder characterized by the accumulation of misfolded alpha-synuclein protein and Alzheimer Diseases characterized by abnormal build-up of two proteins in and around brain cells. Our pipeline targets this pathological protein with precision, aiming to halt its destructive progression and alleviate the debilitating symptoms that rob individuals of their quality of life.
We are also expanding our therapeutic reach to encompass rare neurological diseases such as Adrenoleukodystrophy (ALD) and Adrenoleukomyeloneuropathy (AMN), rare X-linked disorders that disrupt the metabolism of very long-chain fatty acids. Our next-gen vectorized gene therapy approach holds the potential to restore normal cellular function and alleviate the devastating neurological consequences of these disorders.
Focusing on Next- Gen Vectors to Deliver Gene Therapy with Precision
Our current pipeline of therapeutics for neurodegenerative diseases uses novel non-viral and AAV vectors that can more efficiently and effectively deliver the therapy to the targeted areas. Leveraging our decades of experience in nano-science technology with cutting-edge genomic therapeutic targets, Canary is poised to develop a comprehensive and lasting solution for the most difficult diseases to treat.
Pioneering Treatments for Rheumatoid Arthritis
Within our pipeline, we are spearheading groundbreaking research aimed at curing Rheumatoid Arthritis (RA), an autoimmune disorder that causes chronic inflammation and joint damage. Our approach utilizes cutting-edge gene therapy to modulate the immune system and halt the destructive processes underlying RA.
Companion Diagnostics for Early Detection and Intervention
In conjunction with our therapeutic efforts, we are also developing novel companion diagnostics that leverage miRNA biomarkers sourced from partner human clinical trials. These diagnostics hold the potential to detect complex diseases and cancers at their earliest stages, enabling timely intervention and maximizing the efficacy of our therapeutic approaches.
Active Preclinical Studies and Clinical Trials
Our commitment to translating scientific breakthroughs into tangible patient benefits is evident in our active preclinical studies and our commitment to develop clinical trials for targeted therapeutic areas. These studies are paving the way for the development of innovative treatments that offer renewed hope for individuals facing debilitating diseases.
Partnering for Progress
We are dedicated to fostering collaborative partnerships that accelerate the development of our transformative therapies. We regularly engage with key partners to share pipeline updates and explore new avenues for therapeutic advancement.
Our Vision: Preserving Human Life
At the heart of our endeavors lies an unwavering commitment to preserving human life. Our pipeline of vectorized gene therapies represents a beacon of hope for individuals facing CNS proteinopathies and rare neurological diseases. We are driven by the unwavering belief that these groundbreaking therapies have the potential to halt disease progression, restore function, and transform the lives of countless individuals.
Canary DigiGENE miRNA Diagnostic overview
Our point of care diagnostic platform uses Al to read miRNA expression patterns in complex diseases at the earliest stages.
Studies have shown a clear distinction in miRNA expression patterns between disease sample and normal healthy samples. This is a heat map of four breast cancer patients showing separation of miRNA expression profiles in tumors and normal tissues.
